AMIODARONE HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for amiodarone hydrochloride and what is the scope of patent protection?
Amiodarone hydrochloride
is the generic ingredient in four branded drugs marketed by Acella, Bedford, Bedford Labs, Ben Venue, Dr Reddys, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma Farmaceutica, Hospira, Intl Medication Sys, Mylan Institutional, Par Sterile Products, Wyeth Pharms Inc, Baxter Hlthcare, Aurobindo Pharma Ltd, Chartwell Rx, Dr Reddys Labs Sa, Mylan, Rubicon, Taro, Teva, Teva Pharms, Unichem, Upsher Smith Labs, Zydus Pharms Usa Inc, and Wyeth Pharms, and is included in thirty-four NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.Amiodarone hydrochloride has twenty-nine patent family members in thirteen countries.
There are ten drug master file entries for amiodarone hydrochloride. Thirty-one suppliers are listed for this compound.
Summary for AMIODARONE HYDROCHLORIDE
International Patents: | 29 |
US Patents: | 1 |
Tradenames: | 4 |
Applicants: | 28 |
NDAs: | 34 |
Drug Master File Entries: | 10 |
Finished Product Suppliers / Packagers: | 31 |
Raw Ingredient (Bulk) Api Vendors: | 111 |
Clinical Trials: | 161 |
Patent Applications: | 1,086 |
Formulation / Manufacturing: | see details |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for AMIODARONE HYDROCHLORIDE |
What excipients (inactive ingredients) are in AMIODARONE HYDROCHLORIDE? | AMIODARONE HYDROCHLORIDE excipients list |
DailyMed Link: | AMIODARONE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for AMIODARONE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
OHSU Knight Cancer Institute | Phase 2 |
Kun Hua | Phase 4 |
Rush University Medical Center | N/A |
Pharmacology for AMIODARONE HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Baxter Hlthcare | NEXTERONE | amiodarone hydrochloride | INJECTABLE;INJECTION | 022325-001 | Dec 24, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Baxter Hlthcare | NEXTERONE | amiodarone hydrochloride | INJECTABLE;INJECTION | 022325-001 | Dec 24, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Baxter Hlthcare | NEXTERONE | amiodarone hydrochloride | INJECTABLE;INJECTION | 022325-001 | Dec 24, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Baxter Hlthcare | NEXTERONE | amiodarone hydrochloride | INJECTABLE;INJECTION | 022325-002 | Nov 16, 2010 | ⤷ Sign Up | ⤷ Sign Up |
Baxter Hlthcare | NEXTERONE | amiodarone hydrochloride | INJECTABLE;INJECTION | 022325-003 | Nov 16, 2010 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for AMIODARONE HYDROCHLORIDE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
New Zealand | 589290 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | ⤷ Sign Up |
Japan | 2015110671 | スルホアルキルエーテルシクロデキストリン組成物 (SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS) | ⤷ Sign Up |
Japan | 6276828 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 2009134347 | ⤷ Sign Up | |
Japan | 2012072160 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITION | ⤷ Sign Up |
Mexico | 352459 | COMPOSICIONES DE ETER-SULFOALQUILICO-CICLODEXTRINA. (SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS.) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.